Hospital Universitario Insular de Gran Canaria
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · Martin Reck, Delvys Rodríguez‐Abreu, et al. · New England Journal of Medicine
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
2018 · Leena Gandhi, Delvys Rodríguez‐Abreu, et al. · New England Journal of Medicine
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
2012 · Rafael Rosell, Enric Carcereny, et al. · The Lancet Oncology